Comparative Pharmacology
Head-to-head clinical analysis: OXACILLIN SODIUM versus PENBRITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXACILLIN SODIUM versus PENBRITIN.
OXACILLIN SODIUM vs PENBRITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxacillin is a penicillinase-resistant beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking the transpeptidation step in peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamase.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and preventing peptidoglycan cross-linking, leading to cell lysis.
1-2 grams IV every 4-6 hours.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
0.3-0.8 hours in adults with normal renal function; prolonged to 1-2 hours in neonates and 2-5 hours in patients with severe renal impairment (CrCl <10 mL/min)
0.5-1 hour in normal renal function; extended to 2-6 hours in renal impairment. Hemodialysis shortens half-life.
Renal (70-80% unchanged by tubular secretion and glomerular filtration); biliary (minor, approximately 10%)
Renal: ~75-90% unchanged via glomerular filtration and tubular secretion. Biliary: ~10% in feces. Minor hepatic metabolism to penicilloic acid.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic